Single User License
INR 136340
Site License
INR 272680
Corporate User License
INR 409020

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Gastrointestinal Stromal Tumor (GIST)-Pipeline Review, H1 2015

Gastrointestinal Stromal Tumor (GIST)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Gastrointestinal Stromal Tumor (GIST)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Gastrointestinal Stromal Tumor (GIST)-Pipeline Review, H1 2015', provides an overview of the Gastrointestinal Stromal Tumor (GIST)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Gastrointestinal Stromal Tumor (GIST) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Gastrointestinal Stromal Tumor (GIST) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Gastrointestinal Stromal Tumor (GIST) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Gastrointestinal Stromal Tumor (GIST) Overview 9

Therapeutics Development 10

Pipeline Products for Gastrointestinal Stromal Tumor (GIST)-Overview 10

Pipeline Products for Gastrointestinal Stromal Tumor (GIST)-Comparative Analysis 11

Gastrointestinal Stromal Tumor (GIST)-Therapeutics under Development by Companies 12

Gastrointestinal Stromal Tumor (GIST)-Therapeutics under Investigation by Universities/Institutes 14

Gastrointestinal Stromal Tumor (GIST)-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Gastrointestinal Stromal Tumor (GIST)-Products under Development by Companies 18

Gastrointestinal Stromal Tumor (GIST)-Products under Investigation by Universities/Institutes 20

Gastrointestinal Stromal Tumor (GIST)-Companies Involved in Therapeutics Development 21

AB Science 21

Advenchen Laboratories, LLC 22

Ariad Pharmaceuticals, Inc. 23

Array BioPharma Inc. 24

Astex Pharmaceuticals, Inc. 25

Blueprint Medicines 26

Boston Biomedical, Inc. 27

Chipscreen Biosciences Ltd 28

Daiichi Sankyo Company, Limited 29

Deciphera Pharmaceuticals, LLC 30

F. Hoffmann-La Roche Ltd. 31

GlaxoSmithKline plc 32

Jiangsu Hengrui Medicine Co., Ltd. 33

Natco Pharma Limited 34

Nerviano Medical Sciences S.r.l. 35

Novartis AG 36

Otsuka Holdings Co., Ltd. 37

Plexxikon Inc. 38

Synta Pharmaceuticals Corp. 39

Takeda Pharmaceutical Company Limited 40

Threshold Pharmaceuticals, Inc. 41

Gastrointestinal Stromal Tumor (GIST)-Therapeutics Assessment 42

Assessment by Monotherapy Products 42

Assessment by Combination Products 43

Assessment by Target 44

Assessment by Mechanism of Action 47

Assessment by Route of Administration 50

Assessment by Molecule Type 52

Drug Profiles 54

(dabrafenib mesylate + trametinib dimethyl sulfoxide)-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

alpelisib-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

apatinib-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

BBI-503-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

binimetinib-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

BLU-285-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

buparlisib hydrochloride-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

crenolanib besylate-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

CS-2164-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

DCC-2618-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

evofosfamide-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

ganetespib-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

LOP-628-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

masitinib-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

motesanib diphosphate-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

nilotinib-Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

NMSP-088-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

NRCAN-019-Drug Profile 101

Product Description 101

Mechanism of Action 101

R&D Progress 101

onalespib-Drug Profile 103

Product Description 103

Mechanism of Action 103

R&D Progress 103

OPB-51602-Drug Profile 106

Product Description 106

Mechanism of Action 106

R&D Progress 106

pazopanib hydrochloride-Drug Profile 108

Product Description 108

Mechanism of Action 108

R&D Progress 108

PLX-3397-Drug Profile 114

Product Description 114

Mechanism of Action 114

R&D Progress 114

ponatinib hydrochloride-Drug Profile 116

Product Description 116

Mechanism of Action 116

R&D Progress 116

quizartinib dihydrochloride-Drug Profile 118

Product Description 118

Mechanism of Action 118

R&D Progress 118

SF-1126-Drug Profile 121

Product Description 121

Mechanism of Action 121

R&D Progress 121

SHR-1020-Drug Profile 123

Product Description 123

Mechanism of Action 123

R&D Progress 123

Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor-Drug Profile 125

Product Description 125

Mechanism of Action 125

R&D Progress 125

vemurafenib-Drug Profile 126

Product Description 126

Mechanism of Action 126

R&D Progress 126

Gastrointestinal Stromal Tumor (GIST)-Recent Pipeline Updates 129

Gastrointestinal Stromal Tumor (GIST)-Dormant Projects 182

Gastrointestinal Stromal Tumor (GIST)-Discontinued Products 183

Gastrointestinal Stromal Tumor (GIST)-Product Development Milestones 184

Featured News & Press Releases 184

Apr 19, 2015: Blueprint Medicines Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity of BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets 184

Apr 08, 2015: Blueprint Medicines to Present New Preclinical Data on BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets at Upcoming AACR Annual Meeting 185

Jun 01, 2014: ARIAD Announces Initial Data from Phase 2 Trial of Ponatinib in Patients with Gastrointestinal Stromal Tumors 185

Mar 20, 2014: CHMP Adopts Negative Opinion For AB Science's Masican 186

Oct 09, 2013: ARIAD Announces Changes in the Clinical Development Program of Iclusig 187

Jun 11, 2013: Ariad Pharma Initiates Phase II Trial Of Ponatinib In Patients With Gastrointestinal Stromal Tumors 188

Jun 02, 2013: Threshold Pharma Announces Data From Two Ongoing Phase I/II Trials Of TH-302 At 2013 ASCO Annual Meeting 189

Apr 09, 2013: Ariad Pharma Presents New Preclinical Data Showing Ponatinib Overcomes Resistant Mutations In Oncogenic Driver Of Gastrointestinal Stromal Tumors 191

Mar 20, 2013: Ariad Pharma Announces Presentations Of Preclinical Data On Iclusig At AACR Annual Meeting 191

Oct 04, 2012: AB Science Announces Acceptance Of Marketing Application For Masitinib By EMA To Treat Gleevec-resistant Gastro-intestinal Stromal Tumor 191

Appendix 193

Methodology 193

Coverage 193

Secondary Research 193

Primary Research 193

Expert Panel Validation 193

Contact Us 193

Disclaimer 194

List of Tables

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2015 10

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST)-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Development by Companies, H1 2015 (Contd..1) 13

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Products under Development by Companies, H1 2015 18

Products under Development by Companies, H1 2015 (Contd..1) 19

Products under Investigation by Universities/Institutes, H1 2015 20

Gastrointestinal Stromal Tumor (GIST)-Pipeline by AB Science, H1 2015 21

Gastrointestinal Stromal Tumor (GIST)-Pipeline by Advenchen Laboratories, LLC, H1 2015 22

Gastrointestinal Stromal Tumor (GIST)-Pipeline by Ariad Pharmaceuticals, Inc., H1 2015 23

Gastrointestinal Stromal Tumor (GIST)-Pipeline by Array BioPharma Inc., H1 2015 24

Gastrointestinal Stromal Tumor (GIST)-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 25

Gastrointestinal Stromal Tumor (GIST)-Pipeline by Blueprint Medicines, H1 2015 26

Gastrointestinal Stromal Tumor (GIST)-Pipeline by Boston Biomedical, Inc., H1 2015 27

Gastrointestinal Stromal Tumor (GIST)-Pipeline by Chipscreen Biosciences Ltd, H1 2015 28

Gastrointestinal Stromal Tumor (GIST)-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 29

Gastrointestinal Stromal Tumor (GIST)-Pipeline by Deciphera Pharmaceuticals, LLC, H1 2015 30

Gastrointestinal Stromal Tumor (GIST)-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 31

Gastrointestinal Stromal Tumor (GIST)-Pipeline by GlaxoSmithKline plc, H1 2015 32

Gastrointestinal Stromal Tumor (GIST)-Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 33

Gastrointestinal Stromal Tumor (GIST)-Pipeline by Natco Pharma Limited, H1 2015 34

Gastrointestinal Stromal Tumor (GIST)-Pipeline by Nerviano Medical Sciences S.r.l., H1 2015 35

Gastrointestinal Stromal Tumor (GIST)-Pipeline by Novartis AG, H1 2015 36

Gastrointestinal Stromal Tumor (GIST)-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 37

Gastrointestinal Stromal Tumor (GIST)-Pipeline by Plexxikon Inc., H1 2015 38

Gastrointestinal Stromal Tumor (GIST)-Pipeline by Synta Pharmaceuticals Corp., H1 2015 39

Gastrointestinal Stromal Tumor (GIST)-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 40

Gastrointestinal Stromal Tumor (GIST)-Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 41

Assessment by Monotherapy Products, H1 2015 42

Assessment by Combination Products, H1 2015 43

Number of Products by Stage and Target, H1 2015 45

Number of Products by Stage and Mechanism of Action, H1 2015 48

Number of Products by Stage and Route of Administration, H1 2015 51

Number of Products by Stage and Molecule Type, H1 2015 53

Gastrointestinal Stromal Tumor (GIST) Therapeutics-Recent Pipeline Updates, H1 2015 129

Gastrointestinal Stromal Tumor (GIST)-Dormant Projects, H1 2015 182

Gastrointestinal Stromal Tumor (GIST)-Discontinued Products, H1 2015 183

List of Figures

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2015 10

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST)-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Products, H1 2015 17

Assessment by Monotherapy Products, H1 2015 42

Number of Products by Top 10 Targets, H1 2015 44

Number of Products by Stage and Top 10 Targets, H1 2015 44

Number of Products by Top 10 Mechanism of Actions, H1 2015 47

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 48

Number of Products by Top 10 Routes of Administration, H1 2015 50

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 51

Number of Products by Top 10 Molecule Types, H1 2015 52

Number of Products by Stage and Top 10 Molecule Types, H1 2015 53

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AB Science

Advenchen Laboratories, LLC

Ariad Pharmaceuticals, Inc.

Array BioPharma Inc.

Astex Pharmaceuticals, Inc.

Blueprint Medicines

Boston Biomedical, Inc.

Chipscreen Biosciences Ltd

Daiichi Sankyo Company, Limited

Deciphera Pharmaceuticals, LLC

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline plc

Jiangsu Hengrui Medicine Co., Ltd.

Natco Pharma Limited

Nerviano Medical Sciences S.r.l.

Novartis AG

Otsuka Holdings Co., Ltd.

Plexxikon Inc.

Synta Pharmaceuticals Corp.

Takeda Pharmaceutical Company Limited

Threshold Pharmaceuticals, Inc.

Gastrointestinal Stromal Tumor (GIST) Therapeutic Products under Development, Key Players in Gastrointestinal Stromal Tumor (GIST) Therapeutics, Gastrointestinal Stromal Tumor (GIST) Pipeline Overview, Gastrointestinal Stromal Tumor (GIST) Pipeline, Gastrointestinal Stromal Tumor (GIST) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com